Z MAVENS ‘cn WO.: LA7297WwIs81PL.CO84226 25% May, 2016 To, ‘The Secretary, ‘The Calcutsa Stock Exchange Limited 7, Lyons Range, Kolkata~700 001 SUB: Submission of Audited Financial Results and Audit Report for the Quarter and Year ended 31% March, 2016 Dear Sir, Pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wwish to inform you that the "1/2016-17" Meeting of Board of Directors of the Company held at its Registered Office on Wednes¢ay, 25% May, 2016 (which commenced at 2.00 P.M. and concluded 2.55 P.M.) wherein they have adopted / approved: 1) The Audited Financial Results of the Company for 4 quarter and Year ended 31.03.2016 along with the Statement of Assets and Liabilities. 2) FormA (for Audit Report with unmodified opinion) - Standalone 3) Auditor's Report on the Audited Financial Report. The said results will be duly published in the newspapers within due course of time. Request you to kindly take the above on record. ‘Thanking you, Yours faithfully, For Maveas Biotech Limited KLOlES Lar LR Rahul Fuifagar ly ra)= 4 Chairman (a KOLKATA} DIN: 02182260 ZS eo Encl: As above C.C. te Dy. General Manager, Corporate Relationship Department, BSE Ltd, P. J. Tower, ‘Mumbai - 400 001g MAVENS CN No. L17297WB19810L0034226 Sterne of Sanaatons (Convotdaoa Audited ¥nanclal Reza or te dh Guavar and Voor Ended Sint March 016 PARTI Teena) ars Fae Fronte | Precadngs | Coverponding | Vesrtodste ] Yesrto date (G1yos/201e)} (31/22/2015) | (3/03/2015)im | curren perog | previous year theprevious | ended ended yesr | (sx/03/2026)_| cs1/o/2015) Budied —| “Grsaaied | — Rue ‘Audited | Ausites a) We aes / Income From operations Net ot 282) za) ssa ss] 105s] forse our) |e) ore operating ncome 04 004 004 0.09 ad Jott income rom operation (net) ss.) 2249} aaa] ee] aos, a) cos of materia consumed 09] 209 209 0.04 oo) lt) Porenaees of sockin ease 8 09 8 0.09 00 |e) changes in inentorie of Piched goods, 09 09 a9 oq aco) lar employee bonetts expense sei 56 sa za] zal le) Depreciation and-smortton expense 3a] 324 aaa war ars] in otrerexsensestary item exceeding 10% of seq 0] 2203 aor} [nests excensrrelacrgto contioaing Japecstons tobe shown separately) [rota oxpenser x29) vray] 2059] ros] r00. 3 |proi/ .ss) rom operations betore other oss sa] 34 ial 227] |ncome, nance costs and exceptional tems ( la 5 [pri / oss om ordinary setvties before as sa a3 224] na finance ests and exceptional items (34) 7 Jorot Loss from orinary actives ater aa sa 1.34 224) no linance east ut before exceptional ers ( lo 8 [scestiona ems 209 209 0.09} 0.04 oo) 9 rot / Las) rom ersinary stv betore os san] 234 224) nal see) 11 uct one/Les) trom ordinary activites ter os sa] 134 a3 225] astseto) 12 |esaorinry items (ne of tax enpentet 04 0 04 004 oy ase) 13, et oft (Lots) forthe period 142 32) oss su] aq a3 1255] 14 [share of Prot / oss of assocates* oq oq 204 09 009 15. inert meres” 2.09 oo) 209 00 0 16. uct ott Low) after tne, minarty interest ass sx] 134] 234 ns snd share of proft /(oss a ssocistes (13 + fae 35) 137 aiden ect share capital 099.2] 1039.2 208929 029.20) r090.29 [race value ofthe Share shal be indents 109 100) 100) 1.00 1.09 181 [earnings Per share (before extraordinary tems) of” /-eaeh (not snmuaind layease 00 2003 coal 009 oxy Joi ctures oon 005 0.001} 0a oon] 19.1 [earnings Por Share (after estraorainary items) ot a/esen (not annua fapease 00 003 0a} 009} oon are 2.034 2005} 2.04 2.009 ou Z(KOLRATA we ve | }EMAVENS ‘INNO. L7297Wo1982°LC034226, "Raartar Re prIng PREM ENTTES REVERS, RET d CaphaT eplayeT STONER He GUSTY FER fr the ath Giarter and ‘eor ended 31/03/2036 Tea ‘nied | montsended | monthrended(| ‘igurestor’ | ‘igures tor (ax/oa/20x6)| “aasiz/zois) | 3103/2013) n | current period | previous ye exferroe | G3709/2015) [ne sterincorne ror each segment shoud be segment = (ate oF agricutual seal nas) 991 a8} 105.3) rma) er natiocates ood oo) 09 004 0.9 et sates/income From Operations say za wi 5 nt Results Profile tos () before sy seemene Sale of Agcutra! os sa aad saa nae Jcommodes) lor Unavocates od od a4 eo ood tes: nteroste* o0) oo) 3.09 oa) 3c |omer Un-atocabe expenature ne oft 80 oa 9x oo oo in Unsties be income 09 oa 2.9 | od b-espiel raved iseementasets~ Segment Labites) sr seamens sate of Agnew! sorz.agl ors. s91407 siaa] sors Jcommoctes) fe Unatocates 204 0d od ee ood Statement of Asnots and Linbiition a at 91mt March, 2016 (amount in Lacs) Jo) Omner current haben 2oas aise Joes ansete Sub-total - Current soltco. aaoe Sass “roTay. eet aase-a7 Tass , S MS KOLKATA 12 JZ g MAVENS ‘cn No.: L1729708198iPLCOB4226 Notes: 1. The above Financial results have been reviewed by the Audit committee and adopted by the Board of Directors at their meeting held on 25% May, 2016. 2, Segment Revenue: Revenue for this quarter comes from one activity, ie., Trading in Agricultural Commodities and it’s allied products. 3. Provision for taxation is made on the taxable income for the full year in accordance with the provision of Income Tax Act, 1961. 4, Figures of the previous period/year have been regrouped wherever necessary, By order of the Board For Mavens Biotech Limited Lise (Rahul Fulfagar) Chairman DIN: 02182260 Place :Kolkata Date :25.05.2016Mavens | > Biotech Limited ‘NNO LaT297We1saiPLeo342%6 FORMA or mudiereport vith unmodified opinion) As per Regulation 33-of the SEBI (Listing Obligations anid Disclosure Requireiments) | tegulations, 2015 | | (RT Naas offic compan ~ [Mavens Biotech Limned | | | Annual financial statements forthe year ended [31* March 2016 (Standalone) ; |S: See orAuai observation —~ Ua Modified | |. [Ftequeney of cbservation ‘Not Applicable 4 | For Mavens Biotech Limited Aa RshalWolltagar Chairman, -— Paeier DIN: 02182260 M.No. 09096 For Mavens Biotech Linkited notte, ForMavens Biotech Limited ie Se oe 2 Ke LKATA Sea ryan "ie } raige Suliat as Us FO Singhi hist Finanetal Officer fay 62”/ ini 06308454 (PAN: CHPPS94320 2 Auudi{Coniittee Chatman 4 Floor, No, # live Row Kolkata ~700 003, Tel: #91-33-22623056. ae OH er unascomenliacom * atte ewumarnsiachtoeMOHINDRA ARORA & CO. BRAN( I CHARTERED ACCOUNTANT Darya Reger aes, 3rd Floor, Room No. 31, 67-69, fo Maharishi Karve Marg, Marine Lines, Mumbai -400 002 Tol. 022 - 69680888 small : mohindraarora2010@gmail com Annexure VII Auditor’s Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 To, Board of Directors of Mavens Biotech Limited We have audited the quarterly financial results of Mavens Biotech Limited for the quarter ended 31" March, 2016 and the year to date results for the period 01" April, 2015 to 31% March, 2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEB (Listing Ooligations and Diselosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the related financial statements, which are the responsibility of the company’s management and approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. We conducted our audit in accordance with the auditing standards generally accepted in India, Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion. In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results: (j) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and (ii) give a true and fair view of the net profit and other financial information for the quarter ended 3 March, 2016 as well as the year to date results for the period from I" April, 2015 to 31% March, 2016. For Mohindra Arora & Con Chartered Accountants.— ae AAbhok Kumar Katia Partner ‘M. No. 09096 Place: Mumbai Date : 25/95/2016 HE/D OFFICE : Kothi No, 26A, C-Block, 3rd Floor, Guru Virja Nand Marg, Vikashpuri, New Delhi -110 018. Tel.: 2571 7213 | 25507356, Fax : 2575 3570